WO1993006827A1 - Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use - Google Patents
Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use Download PDFInfo
- Publication number
- WO1993006827A1 WO1993006827A1 PCT/US1992/008600 US9208600W WO9306827A1 WO 1993006827 A1 WO1993006827 A1 WO 1993006827A1 US 9208600 W US9208600 W US 9208600W WO 9306827 A1 WO9306827 A1 WO 9306827A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- thiadiazole
- ethyl
- phenyl
- percent
- Prior art date
Links
- 0 CCC(C)(CNC(COc1n[s]nc1*)O)CO Chemical compound CCC(C)(CNC(COc1n[s]nc1*)O)CO 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- This invention relates to topical ophthalmic compositions comprising certain 4-(3-substituted amino-2-hydroxypropoxy)-l,2,5- thiadiazoles. These compounds are ⁇ -blockers which are effective at relatively low doses. Ophthalmic compositions comprising these compounds are useful in the treatment of glaucoma and ocular hypertension.
- topical ophthalmic compositions comprising the thiadiazoles of the present invention contain a higher concentration of active than corresponding ophthalmic compositions containing timolol, but cause fewer systemic side effects.
- Figure 1 is a graph of time (hr) versus mean percent change in heart rate (beats per minute).
- the thiadiazoles of the present invention have the following general formula:
- R represents: (1) hydrogen; (2) halogen, preferably chloro or bromo; (3) C 5 lower alkyl having either a straight or branched chain such as methyl, ethyl, propyl, isopropyl, butyl iso-, secondary- or tert-butyl and amyl, including all of its branched chain configurations; (4) C 2 .
- lower alkenyl such as vinyl, allyl, ethallyl and the like
- a group having the structure Y-X-Z- wherein Y is either a straight or branched chain C 1-4 alkyl optionally substituted with a phenyl group or a phenyl optionally substituted with one or more halogen atoms (especially chloro, bromo, fluoro), hydroxy, C ⁇ lower alkyl or alkoxy, X is oxygen or sulfur and Z is a C ⁇ alkyl;
- cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; (8) C 1 _ 5 lower alkoxy, either a straight or branched chain and including methoxy, ethoxy, propoxy, isopropoxy, butoxy, and pentoxy (the latter groups existing in either straight or branched configuration); (9) phenyl or substituted phenyl, wherein the substitutes are selected from one or more halogen atoms (preferably chloro or fluoro) and a C 1 _ 3 lower alkyl or alkoxy; (10) phenyl-lower alkyl, wherein the lower alkyl moiety is either a straight or branched chain and has from 1 to 4 carbons and the phenyl moiety can be unsubstituted or substituted with one or more halogen atoms (preferably chloro, fluoro, or bromo) or C x _ 3 lower alkyl or
- R 3 represents hydrogen, C ⁇ lower alkyl, a hydroxy- substituted lower alkyl and phenyl, or R 2 and R 3 can be joined together either directly to give a 3 to 7 membered ring with the nitrogen to which they are attached thereby forming aziridinyl, azetidinyl, pyrrolidyl, piperidyl, or a hexahydroazepinyl group, said 3 to 7 membered rings being either unsubstituted or substituted, preferably with one or more C j _ 5 lower alkyl and C ⁇ hydroxy-lower alkyl, or alternatively R 2 and R 3 can be joined through an oxygen, nitrogen or sulfur atom to form a 5 or 6 membered ring, advantageously a morpholino, hexahydropyrimidyl , thiazolidinyl, p- thiazinyl, piperazinyl and the like group optionally
- thiadiazoles may be prepared by the methods disclosed in US 3,655,663 and US 3,729,469 whose entire contents are incorporated by reference herein.
- Preferred thiadiazoles are those of Formula (I), above, wherein R is chloro, ethyl, allyl, cyclopropyl, ethoxy, phenyl, phenyl-chloromethyl, or 2-(cyclopropylmethoxy)ethyl.
- Suitable pharmacologically acceptable salts are acid addition salts derived from inorganic acids, for example, hydrochlorides, hydrobromides, phosphates or sulfates, or salts derived from organic acids, for example, oxalates, lactates, malates, maleates, formates, acetates, succinates, tartrates, salicylates, citrates, phenylacetates, benzoates, p-toluenesulfonates and other salts such as those which provide relatively insoluble products which afford a slow release of the active material, for example, a l.l'-methylene- bis(2-hydroxy-3-naphthoate) and the like.
- inorganic acids for example, hydrochlorides, hydrobromides, phosphates or sulfates
- organic acids for example, oxalates, lactates, malates, maleates, formates, acetates, succinates, tartrates, salicylates, cit
- thiadiazoles are present in the compositions of the present invention at a concentration between about 0.005 and about 5 percent by weight (wt%). It is preferred to have a thiadiazole concentration between about 0.1 and about 2.0 wt%. Most preferably, the thiadiazole concentration is about 1.0 wt%.
- compositions of the present invention may be prepared by combining one or more of the thiadiazoles of the present invention with a suitable vehicle to form a solution, dispersion or gel.
- These compositions may additionally include finely divided ion exchange resins and/or anionic mucomimetic polymer for enhanced bioavailability and efficacy, as well as for patient comfort.
- finely divided ion exchange resins and anionic mucomimetic polymers in ophthalmic compositions are detailed in U.S. Patent No. 4,911,920 (Jani et al.), whose entire contents are hereby incorporated by reference herein.
- compositions of the present invention may also include one or more ingredients conventionallyfound in ophthalmic formulations, such as preservatives (e.g., benzalkonium chloride or thi erosal), viscosity-imparting agents (e.g., polyvinyl alcohol or hydroxypropyl methylcellulose) and tonicity agents (e.g., sodium chloride or mannitol).
- preservatives e.g., benzalkonium chloride or thi erosal
- viscosity-imparting agents e.g., polyvinyl alcohol or hydroxypropyl methylcellulose
- tonicity agents e.g., sodium chloride or mannitol
- the compositions will also normally include buffering agents, such as phosphates and citrates, to maintain the pH within the range of physiological pH (between 6.0 and 7.5). Hydrochloric acid or sodium hydroxide will typically be used to adjust the pH of the resultant composition.
- Table 1 represents some preferred compositions of the present invention.
- Formulations 1-3 containing finely divided ion exchange resins, may be prepared by first dissolving the drug in water and then slowly dispersing the resin into the solution to form a suspension. Mannitol previously dissolved in an aliquot of water and mixed with benzalkonium chloride is then added to the suspension. Carbopol® 934P is then added to obtain the desired viscosity. The resultant composition can then be suitably sterilized and filled into previously sterilized containers.
- Formulations 4-6 may be prepared by dissolving the drug in water, along with the other ingredients. Water is then added to bring the solution to 100% and the pH is adjusted. The resultant composition can then be suitably sterilized and filled into suitable packaging for ocular administration.
- EXAMPLE 2 A study was conducted to determine the effect on the intraocular pressure of cynomolgus monkeys after a single topical instillation of a composition of the present invention. Prior to the commencement of the study, the right eyes of all of the monkeys had been given laser trabeculoplasty, which resulted in ocular hypertension in the lasered eyes. All of the left eyes were normal and normotensive. The animals had also been trained to sit in "restraint chairs” and conditioned to accept the pressure measurements without general anesthesia.
- IOP was determined using an Alcon Pneumatonograph (Alcon Laboratories, Inc., Fort Worth, Texas) after light corneal anesthesia with proparacaine. Following each measurement, the residual anesthetic was washed out with saline. The results are shown in Table 2, below.
- composition of the present invention reduces IOP in hypertensive eyes by more than 25% for a period of at least 6 hours after treatment.
- cornea! sensitivity was measured as a function of blink response.
- the rabbit consistently exhibits a blink of the eyelid when the cornea is touched with sufficient force. This is a protective reflex which is absent when the cornea is anestetized.
- NZA rabbits were assigned to each of three test groups. The eyelashes were trimmed and one eye of each animal selected for use.
- a 1% solution of 3-ethy!-4-[3-N-(2-hydroxymethylprop-2- yl)amino] hydroxypropoxy-1,2,5-thiadiazole (a composition of the present invention) was administered to the selected eye of each animal in one group and either acetate buffered saline or comrnercial!y available Timoptic ® (Merck, Sharp & Doh e, West Point, Pennsylvania) were administered to the selected eye of each animal in the other groups.
- Heart rate was measured with a stethoscope held to the chest of each animal. The beats in two 15 second intervals were recorded and the two recordings averaged. In addition to the baseline measurements,- heart rate was measured at 0.5, 1, 1.5, 2.5 and 3.5 hours after baseline and at 0.5, 1, 1.5, 2.5 and 3.5 hours after treatment with beta-blocker or vehicle. The results are shown in Table 4, below, and in Figure 1.
- the results show that, although the heart rate in both groups increased, the monkeys in Group II experienced a greater increase in heart rate than those in Group I (this is best observed in Figure 1). It therefore appears that topical application of a composition of the present invention partially suppresses isoproterenol-induced tachycardia in conscious cynomolgus monkeys.
- the present invention is also directed to use of the composition of the invention in treating and controlling ocular hypertension associated with glaucoma and other ophthalmic diseases and abnormalities.
- the methods comprise topically applying to the affected eye(s) of the patient a therapeutically effective amount of a composition according to the present invention. The frequency and amount of dosage will be determined by the clinician based on various clinical factors.
- the methods will typically comprise topical application of one or two drips (a drop is approximately 30 micro!iters), or am equivalent amount of a solid or semi-solid dosage form, to the affected eye one to two times per day.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU28696/92A AU660735B2 (en) | 1991-10-11 | 1992-10-09 | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
EP92922070A EP0606393A1 (en) | 1991-10-11 | 1992-10-09 | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
JP5506451A JPH06511242A (en) | 1991-10-11 | 1992-10-09 | Topical eye drop compositions containing 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77654491A | 1991-10-11 | 1991-10-11 | |
US776,544 | 1991-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993006827A1 true WO1993006827A1 (en) | 1993-04-15 |
Family
ID=25107688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/008600 WO1993006827A1 (en) | 1991-10-11 | 1992-10-09 | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0606393A1 (en) |
JP (1) | JPH06511242A (en) |
AU (1) | AU660735B2 (en) |
CA (1) | CA2120603A1 (en) |
WO (1) | WO1993006827A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1925956A1 (en) * | 1968-05-22 | 1969-11-27 | Frosst & Co Charles E | Chemical processes and products |
US3655663A (en) * | 1969-04-21 | 1972-04-11 | Burton K Wasson | 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles |
WO1984002525A1 (en) * | 1982-12-22 | 1984-07-05 | American Hospital Supply Corp | Esters of 3-(3-substituted-amino-2-hydroxypropoxy)-4-substituted-1,2,5-thiadiazole derivatives |
EP0429732A1 (en) * | 1986-07-30 | 1991-06-05 | Alcon Laboratories, Inc. | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers |
-
1992
- 1992-10-09 AU AU28696/92A patent/AU660735B2/en not_active Ceased
- 1992-10-09 EP EP92922070A patent/EP0606393A1/en not_active Withdrawn
- 1992-10-09 WO PCT/US1992/008600 patent/WO1993006827A1/en not_active Application Discontinuation
- 1992-10-09 JP JP5506451A patent/JPH06511242A/en active Pending
- 1992-10-09 CA CA002120603A patent/CA2120603A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1925956A1 (en) * | 1968-05-22 | 1969-11-27 | Frosst & Co Charles E | Chemical processes and products |
US3655663A (en) * | 1969-04-21 | 1972-04-11 | Burton K Wasson | 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles |
WO1984002525A1 (en) * | 1982-12-22 | 1984-07-05 | American Hospital Supply Corp | Esters of 3-(3-substituted-amino-2-hydroxypropoxy)-4-substituted-1,2,5-thiadiazole derivatives |
EP0429732A1 (en) * | 1986-07-30 | 1991-06-05 | Alcon Laboratories, Inc. | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers |
Non-Patent Citations (4)
Title |
---|
DRUG METABOLISM AND DISPOSITION vol. 8, no. 4, 1980, pages 236 - 240 D.J. TOCCO ET AL. 'TIMOLOL METABOLISM IN MAN AND LABORATORY ANIMALS' * |
GRAEFES ARCHIV OPHTHALMOLOGIE vol. 210, no. 1, 1979, pages 1 - 8 L. BONOMI ET AL. 'COMPARISON OF THE EFFECTS OF NINE BETA-ADRENERGIC BLOCKING AGENTS ON INTRAOCULAR PRESSURE IN RABBITS' * |
JOURNAL OF MEDICINAL CHEMISTRY vol. 15, no. 6, 1972, pages 651 - 655 B.K. WASSON ET AL. 'BETA-ADRENERGIC BLOCKING AGENTS' * |
PH. DOROSZ 'GUIDE PRATIQUE DES MEDICAMENTS' 1987 , MALOINE S.A. , PARIS * |
Also Published As
Publication number | Publication date |
---|---|
AU660735B2 (en) | 1995-07-06 |
EP0606393A1 (en) | 1994-07-20 |
JPH06511242A (en) | 1994-12-15 |
AU2869692A (en) | 1993-05-03 |
CA2120603A1 (en) | 1993-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4934653B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and β-blocker | |
US4599353A (en) | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma | |
JP5174777B2 (en) | Glaucoma treatment agent comprising Rho kinase inhibitor and prostaglandins | |
EP0389995B1 (en) | Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension | |
EP0737475A2 (en) | Treatment and control of ocular development with a muscarinic antagonist | |
US5578638A (en) | Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists | |
JPH08502759A (en) | Use of ergoline derivatives for the treatment of glaucoma | |
EP0478694B1 (en) | use of pirenzepine, telenzepine oder O-methoxy -sila-hexocyclium in the manufacture of a medicament for the TREATMENT AND CONTROL OF OCULAR DEVELOPMENT | |
CA2129037C (en) | Topical antiglaucoma compositions comprising carbonic anhydrase inhibitors and beta-blockers | |
JP7346305B2 (en) | Pharmaceutical preparations containing pyridylaminoacetic acid compounds | |
EP0647445B1 (en) | Composition for prophylaxis and treatment of myopia | |
EP0253717B1 (en) | Combinations of beta-blockers and pilocarpine | |
US5320839A (en) | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use | |
JP4300347B2 (en) | Glaucoma treatment agent consisting of bunazosin and prostaglandins | |
AU660735B2 (en) | Topical ophthalmic compositions comprising 4-(3-substituted amino-2-hydroxypropoxy)-1,2,5-thiadiazoles and methods for their use | |
JP2001519394A (en) | How to use flunarizine for topical treatment of glaucoma | |
KR900004800B1 (en) | Antiglaucoma compositions | |
JP3066561B2 (en) | Myopia prevention / treatment agent | |
Rennie et al. | The effect of a once-daily oral dose of nadolol on intraocular pressure in normal volunteers | |
US5563171A (en) | Treatment of glaucoma and ocular hypertension with β3-adrenergic agonists | |
EP0456988B1 (en) | Use of naproxen as mydriatic agent | |
JP2003026565A (en) | Water-based eye drop containing ketotifen for accelerating transferability to conjunctiva | |
JPH06503563A (en) | Uses of pyridine derivatives in the treatment of ocular hypertension | |
KR20000013487A (en) | Composition for preventing and treating near-sightedness containing glycopyrolate as effective ingredient | |
EP0375319A3 (en) | Angiotensin converting enzyme inhibitors in the treatment of glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2120603 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992922070 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1992922070 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992922070 Country of ref document: EP |